The management of BCR patients has been partially changed by the introduction of 68Ga-PSMA-11 PET/CT imaging, which allows for the early detection and targeting of small-sized PCa relapsing sites, including patients with PSA levels as low as 0.2 ng/mL. This evidence concerns the gene BCR and posterior cortical atrophy.